R&D Trends

Multiple Myeloma Research Foundation to launch “Answer Fund”

Friday, August 4, 2017

The Multiple Myeloma Research Foundation (MMRF) announced that it is investing $5 million over the next three years to launch “The MMRF Answer Fund,” a multifaceted effort to address important questions facing the multiple myeloma community and to advance precision medicine. The Answer Fund will leverage the landmark MMRF CoMMpass study, which is the largest collection of genomic data of any cancer, tracking more than 1,100 myeloma patients over eight years.

[Read More]

US Oncology Research, Epizyme collaborate

Wednesday, August 2, 2017

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US Oncology Research, one of the nation’s largest networks of independent, community-based oncology practices dedicated to advancing high-quality treatments through clinical trials, announced a collaboration to screen and identify relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) patients with EZH2 mutations. Once identified, eligible candidates will be directed to Epizyme’s ongoing phase II clinical trial of tazemetostat, the company’s first-in-class EZH2 inhibitor, as a single-agent treatment for relapsed or refractory patients with FL or DLBCL.

[Read More]

Alexion, Moderna end partnership

Tuesday, August 1, 2017

Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, provided an update on its rare disease Research & Development (R&D) strategy, issuing the following statement related to Alexion Pharmaceuticals R&D realignment announcement.

[Read More]

AstraZeneca, Merck to partner

Friday, July 28, 2017

AstraZeneca and Merck & Co., Inc. have announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.

[Read More]

WHO urges action against HIV drug resistance threat

Tuesday, July 25, 2017

WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries. The Organization warns that this growing threat could undermine global progress in treating and preventing HIV infection if early and effective action is not taken.

[Read More]